HTL0030310 is a potent and selective agonist of the SSTR5 (somatostatin 5) receptor and the sixth molecule designed by the Company using its GPCR Structure-Based Drug Design (SBDD)
Sandoz will market the authorized generic version of Suboxone on behalf of Indivior in the country. Indivior said its decision is based on the market impact expected from
The patent (U.S. Patent Number 10206894) covers methods for treating and/or preventing mucositis with one or more compounds, or pharmaceutically acceptable salts. The new patent broadens the Company’s
The recommended dose of Keytruda for the adjuvant treatment of adult patients with melanoma is 200 mg administered as an intravenous infusion over 30 minutes every three weeks
Under the agreement, Knight will initially lend Moksha8 up to US $25 million in working capital funding, of which US $10 million will be issued at closing. Knight
Additional work conducted on a drug exposure-response analysis showed a statistically significant response of BNC210 in treatment of PTSD symptoms, as measured by Clinician-Administered PTSD Scale (CAPS-5) at
The combination of Bavencia and Inlyta have significantly expanded median PFS by more than five months compared against Sutent (sunitinib) as a first-line treatment for patients with advanced
The artificial intelligence software, created by researchers at Imperial College London and the University of Melbourne, has been able to predict the prognosis of patients with ovarian cancer
Cenobamate is a novel and small molecule investigational antiepileptic drug being developed to treat partial-onset seizures in adult patients. Under exclusive licensing agreement, Arvelle will develop and commercialize
Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Novartis Institutes for BioMedical Research (NIBR), and Osage University Partners also participated in the round along with Vor Co-founder PureTech
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.